Skip to main content

Table 2 Relative risk of severe infectious events with EGFR-MoAbs according to tumor types, EGFR-MoAbs, concomitant therapies and phases of trials

From: Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

Groups Studies, number Severe infectious events, number/total, number RR (95%CI) Pvalue Pvaluefor group difference
EGFR-MoAbs Control
Tumor types       
 CRC 11 276/3801 181/3808 1.42 (1.05 to 1.93) 0.024 0.001
 NSCLC 7 199/1341 137/1344 1.45 (1.19 to 1.77) <0.001
 Head and neck cancer 4 64/810 43/810 1.48 (1.02 to 2.13) 0.037
 Others 4 62/494 77/397 0.72 (0.53 to 0.97) 0.033
Anti-EGFR MoAbs       
 Cetuximab 21 467/4548 299/4465 1.52 (1.33 to 1.75) <0.001 0.092
 Panitumumab 5 134/1898 139/1894 0.99 (0.62 to 1.60) 0.98
Concomitant therapies       
 Cisplatin 8 233/1690 148/1608 1.48 (1.22 to 1.79) <0.001 0.30
 Irinotecan 4 100/942 68/999 1.53 (1.12 to 2.10) 0.008
 Oxaliplatin 8 192/2892 172/2847 0.97 (0.58 to 1.61) 0.90
 Radiotherapy 3 13/312 11/313 0.99 (0.47 to 2.10) 0.98
 Others 3 73/610 39/592 1.80 (1.24 to 2.62) 0.002
Phases of trials       
 Phase II 9 35/514 21/422 1.26 (0.75 to 2.12) 0.39 0.82
 Phase III 17 566/5932 417/593 1.34 (1.08 to 1.67) 0.008
Overall 26 601/6446 438/6359 1.34 (1.10 to 1.62) 0.003 NA
  1. CI, confidence interval; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; NA, not available; NSCLC, non-small-cell lung cancer; RR, relative risk.